CN1111739C - 凝血、纤溶功能动态测定试剂 - Google Patents

凝血、纤溶功能动态测定试剂 Download PDF

Info

Publication number
CN1111739C
CN1111739C CN97100956A CN97100956A CN1111739C CN 1111739 C CN1111739 C CN 1111739C CN 97100956 A CN97100956 A CN 97100956A CN 97100956 A CN97100956 A CN 97100956A CN 1111739 C CN1111739 C CN 1111739C
Authority
CN
China
Prior art keywords
blood plasma
blood
distilled water
milliliter
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN97100956A
Other languages
English (en)
Other versions
CN1190187A (zh
Inventor
许文俊
叶有坤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN97100956A priority Critical patent/CN1111739C/zh
Publication of CN1190187A publication Critical patent/CN1190187A/zh
Application granted granted Critical
Publication of CN1111739C publication Critical patent/CN1111739C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

本发明涉及一种测试血的凝血、纤溶功能动态的测试剂，属于对血的化学检测所用的分析材料技术领域。其组成为(每毫升血浆)：尿激酶50-2000单位、氯化钠0.7-7.0毫克、氯化钙0.2-5毫克、醋酸钠0.5-10毫克、巴比妥钠3-25毫克、盐酸0.02-0.3毫当量、蒸馏水600-6000微升。本发明能同时检测血凝到纤溶的全动态过程，反应两系统动态平衡状态。

Description

凝血、纤溶功能动态测定试剂
                         技术领域
本发明属于对血的化学检测所用的分析材料技术领域(分类号为GO1N33/48)，具体涉及一种测试血的凝血、纤溶功能动态测定试剂。
                         技术背景
正常情况下人的血是液态，血液中有多种凝血固子和抗凝血因子，促凝物质和抗凝物质，这些相互拮抗的固子和物质处于相对平衡，即血凝和纤溶处于动态平衡状态以维持血的液态，保证人体各组织与各器官新陈代谢物质的传递。血凝和纤溶是由一系列酶原转化而形成的酶所催化的复杂变化反应过程，如果凝血因子被激活，就会产生凝血机能亢进，甚至出现高凝状态，引发脑血栓。冠状动脉血栓等，相反则可能出现低凝状态，发生皮下。粘膜。胃肠道及伤口出血。因此，对凝血。纤溶系统活性测定一直为临床医学所关注，但目前医学上所采取的都是单方面地用凝血剂。或纤溶剂分别测试血凝或纤溶的状态，这些试剂无法同时检测两系统活性高低以及检测两系统是否处于动态平衡状态。
                         发明内容
本发明的目的在于针对现有技术存在的不足，提供一种能同时检测出从血液凝固到纤维蛋白溶解全动态过程，从而检测两系统动态平衡状态的凝血。纤溶功能动态检测试剂。
本检测试剂由以下成份组成：
[UK]尿激酶50-2000单位(u)/毫升血浆。(NaCl)氯化钠0.7-7毫克/毫升血浆。(CaCl2)氯化钙0.2-5毫克/毫升血浆。醋酸钠0.5-10毫克/毫升血浆。巴比妥钠3-25毫克/毫升血浆。(HCl)盐酸0.02-0.3毫当量/毫升血浆。(DH2O)蒸馏水600-6000微升/毫升血浆。
为了方便存放，本检测试剂分为A.B.C三组，使用时则混合同时加入：
A组：尿激酶50-2000单位/毫升血浆、氯化钠0.2-2.0毫克/毫升向浆、蒸馏水50-500微升/毫升血浆，为纤溶剂。
B组：氯化钙0.2-5毫克/毫升血浆、蒸馏水50-500微升/毫升血浆，为凝血剂。
C组：醋酸钠0.5-10毫克/毫升血浆、巴比妥钠3-25毫克/毫升血浆、氯化钠0.5-5.0毫克/毫升血浆、盐酸0.02-0.3毫当量/毫升血浆、蒸馏水500-5000微升/毫升血浆，为血浆稀释液。
本检测试剂成份的含量优选范围为：
A组：由尿激酶300-700单位(u)/毫升血浆、氯化钠0.62-1.1毫克/毫升血浆、蒸馏水90-150微升/毫升血浆。
B组：由氯化钙2.85-3.901毫克/毫升血浆、蒸馏水105-200微升/毫升血浆。
C组：由醋酸钠3.21-6.45毫克/毫升血浆、巴比妥钠9.25-19.1毫克/毫升血浆、氯化钠0.93-3.1毫克/毫升血浆、盐酸0.02-0.21毫当量(MN)/毫升血浆、蒸馏水1240-3540微升/毫升血浆。
本凝血，纤溶功能动态测定试剂的作用过程是：当对被检测血浆按比例加入本测试剂后，凝血剂与血浆中的凝血因子发生反应，使其凝血因子活化，经过一系列酶促反应后，液态的纤维蛋白原转变为凝胶态的纤维蛋白；同时由于纤溶剂对血浆中纤维蛋白溶解酶原的激活，纤溶酶原转变为纤维蛋白溶解酶，使凝胶态的纤维蛋白溶解变回液态。这样，血浆从血凝反应开始到纤溶反应结束的全部反应就被客观。全面。动态地反应出来了。
本发明的配制方法为常规配制，使用时按被测血浆的量，按比例一次加入本试剂即可，检测结果由本发明人发明的凝血一纤溶溶动态图仪得出。
本发明能同时检测人体的血液凝血。纤溶两系统活性高低，检测两系统动态平衡状态。有助于医生据此对病人的病情做出准确诊断。
                       具体实施方式
实施例1：(每毫升血浆)
A组：尿激酶220单位(u)。氯化钠0.4毫克。蒸馏水80微升。
B组：氯化钙0.26毫克。蒸馏水100微升。
C组：醋酸钠0.26毫克。巴比妥钠5.37毫克。氯化钠0.89毫克。盐酸0.12毫当量。蒸馏水620微升。
实施例2：(每毫升血浆)
A组：尿激酶900单位(u)。氯化钠1.1毫克。蒸馏水200微升。
B组：氯化钙2.25毫克。蒸馏水285微升。
C组：醋酸钠6.12毫克。巴比妥钠11.26毫克。氯化钠2.42毫克。盐酸0.25毫当量。蒸馏水2600微升。
实施例3：(每毫升血浆)
A组：尿激酶1600单位(u)。氯化钠1.7毫克。蒸馏水400微升。
B组：氯化钙4.67毫克。蒸馏水420微升。
C组：醋酸钠8.47毫克。巴比妥钠21.23毫克。氯化钠4.10毫克。盐酸0.27毫当量。蒸馏水4200微升。
实施例4：(每毫升血浆)
A组：尿激酶50单位(u)。氯化钠0.2毫克。蒸馏水50微升。
B组：氯化钙0.2毫克。蒸馏水50微升。
C组：醋酸钠0.5毫克。巴比妥钠3毫克。氯化钠0.5毫克。盐酸0.02毫当量。蒸馏水500微升。
实施例5：(每毫升血浆)
A组：尿激酶2000单位(u)。氯化钠2.0毫克。蒸馏水500微升。
B组：氯化钙5毫克。蒸馏水500微升。
C组：醋酸钠10毫克。巴比妥钠25毫克。氯化钠5毫克。盐酸0.3毫当量。蒸馏水5000微升。
实施例6：(每毫升血浆)
A组：尿激酶300单位(u)。氯化钠0.62毫克。蒸馏水90微升。
B组：氯化钙2.85毫克。蒸馏水105微升。
C组：醋酸钠3.21毫克。巴比妥钠9.25毫克。氯化钠0.93毫克。盐酸0.02毫当量。蒸馏水1240微升。
实施例7：(每毫升血浆)
A组：尿激酶700单位(u)。氯化钠1.1毫克。蒸馏水150微升。
B组：氯化钙3.901毫克。蒸馏水200微升。
C组：醋酸钠6.45毫克。巴比妥钠19.1毫克。氯化钠3.1毫克。盐酸0.21毫当量。蒸馏水3540微升。

Claims (3)

1、一种凝血、纤溶功能动态测定试剂，其特征在它由尿激酶50-2000单位/毫升血浆、氯化钠0.7-7.0毫克/毫升血浆、氯化钙0.2-5毫克/毫升血浆、醋酸钠0.5-10毫克/毫升血浆、巴比妥钠3-25毫克/毫升血浆、盐酸0.02-0.3毫当量/毫升血浆、蒸馏水600-6000微升/毫升血浆组成。
2、根据权利要求1所述的凝血、纤溶功能动态测定试剂，其特征在于它分为A、B、C三组：
A组由尿激酶50-2000单位/毫升血浆、氯化钠0.2-2.0毫克/毫升血浆、蒸馏水50-500微升/毫升血浆组成。
B组由氯化钙0.2-5毫克/毫升血浆、蒸馏水50-500微升/毫升血浆组成。
C组由醋酸钠0.5-10毫克/毫升血浆、巴比妥钠3-25毫克/毫升血浆、氯化钠0.5-5毫克/毫升血浆、盐酸0.02-0.3毫当量/毫升血浆、蒸馏水500-5000微升/毫升血浆组成。
3、根据权利要求2所述的凝血、纤溶功能动态测定试剂，其特征在于A、B、C三组含量为：
A组由尿激酶300-700单位/毫升血浆、氯化钠0.62-1.1毫克/毫升血浆、蒸馏水90-150微升/毫升血浆组成；
B组由氯化钙2.85-3.901毫克/毫升血浆、蒸馏水105-200微升/毫升血浆组成；
C组由醋酸钠3.21-6.45毫克/毫升血浆、巴比妥钠9.25-19.1毫克/毫升血浆、氯化钠0.93-3.1毫克/毫升血浆、盐酸0.02-0.21毫当量/毫升血浆、蒸馏水1240-3540微升/毫升血浆组成。
CN97100956A 1997-02-04 1997-02-04 凝血、纤溶功能动态测定试剂 Expired - Fee Related CN1111739C (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN97100956A CN1111739C (zh) 1997-02-04 1997-02-04 凝血、纤溶功能动态测定试剂

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN97100956A CN1111739C (zh) 1997-02-04 1997-02-04 凝血、纤溶功能动态测定试剂

Publications (2)

Publication Number Publication Date
CN1190187A CN1190187A (zh) 1998-08-12
CN1111739C true CN1111739C (zh) 2003-06-18

Family

ID=5165430

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97100956A Expired - Fee Related CN1111739C (zh) 1997-02-04 1997-02-04 凝血、纤溶功能动态测定试剂

Country Status (1)

Country Link
CN (1) CN1111739C (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10145626B2 (en) * 2013-11-15 2018-12-04 General Electric Technology Gmbh Internally stiffened extended service heat recovery steam generator apparatus

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1063425A (en) * 1965-01-04 1967-03-30 Grace W R & Co Process for the polymerisation of styrene
US4216291A (en) * 1975-09-19 1980-08-05 Leuven Research & Development V.Z.W. Thrombosis-test
CN1102438A (zh) * 1993-07-15 1995-05-10 格吕伦塔尔有限公司 具改进纤溶特性和凝血酶抑制活性的双功能尿激酶变异体
US5468505A (en) * 1992-02-28 1995-11-21 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1063425A (en) * 1965-01-04 1967-03-30 Grace W R & Co Process for the polymerisation of styrene
US4216291A (en) * 1975-09-19 1980-08-05 Leuven Research & Development V.Z.W. Thrombosis-test
US5468505A (en) * 1992-02-28 1995-11-21 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
CN1102438A (zh) * 1993-07-15 1995-05-10 格吕伦塔尔有限公司 具改进纤溶特性和凝血酶抑制活性的双功能尿激酶变异体

Also Published As

Publication number Publication date
CN1190187A (zh) 1998-08-12

Similar Documents

Publication Publication Date Title
Grip Inflammatory bowel disease promotes venous thrombosis earlier in life
Marder et al. Detection of serum fibrinogen and fibrin degradation products: Comparison of six technics using purified products and application in clinical studies
US7595169B2 (en) Method for determining percent platelet aggregation
Jörneskog et al. Altered properties of the fibrin gel structure in patients with IDDM
CA2032561C (en) Method of determining levels of extrinsic and intrinsic clotting factors and protein c
Williams et al. The effect of acetylsalicylic acid on fibrin gel lysis by tissue plasminogen activator
CN108982865A (zh) 一种血栓弹力图法肝素定量检测试剂盒及其制备方法
Gurewich et al. A comparative study of precipitation and paracoagulation by protamine sulfate and ethanol gelation tests
CN1111739C (zh) 凝血、纤溶功能动态测定试剂
US20070037236A1 (en) Factor Xa-based heparin assay using a heparin-modifying component
Despotis et al. In Vitro reversal of Heparin Effect with Heparinas: evaluation with whole blood Prothrombin Time and activated partial Thromboplastin Time in Cardiac Surgical Patients
JP5212821B2 (ja) スペーサーを介して高分子へ結合する基質を含む修飾基質を用いた酵素測定アッセイ
Plate et al. On the mechanism of enhanced thromboresistance of polymeric materials in the presence of heparin
Bounameaux et al. Laboratory diagnosis of pulmonary embolism: value of increased levels of plasma D-dimer and thrombin—antithrombin III complexes
JP2632525B2 (ja) ヘパリン検定
CN108624680B (zh) Rae1基因或蛋白作为诊断心肌梗死的生物标志物的应用
Nagamatsu et al. Determination of leukocyte elastase concentration in plasma and serum by a simple method using a specific synthetic substrate
CN108796067B (zh) 血液中maea基因的诊断新功能
Retzinger et al. Complexation with heparin prevents adhesion between fibrin-coated surfaces.
US4960694A (en) Test combination and method of detecting fibrin monomers in blood
Yun et al. Electrochemical sensors for polyionic macromolecules: development and applications in pharmaceutical research
Joy et al. Effect of p H on the stability of heparin in 5% dextrose solutions
Guo et al. Homogeneous enzyme-based binding assay for studying glycosaminoglycan interactions with macromolecules and peptides
EP0829725A2 (en) A method for the activation of blood coagulation factor XII
Lynch et al. Preoperative AT-III values and clinical postoperative thrombosis: a comparison of three antithrombin-III assays

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee